Loxo is developing cancer treatments that target a tumors’ genetic markers regardless of where in the body they’re located

US pharma giant Eli Lilly is to buy Loxo Oncology for about $8 billion (€7 billion) in cash, the second multibillion-dollar cancer deal of the year by(...)

Traders working on the floor of the New York Stock Exchange. Photograph: Michael Nagle/Bloomberg

A flurry of merger activity among European stocks drove strong moves on Monday as some regional indexes notched up new records, with investors shruggi(...)

Novartis estimates that only 600 patients a year would be eligible for its new $375,000 therapy. Photograph: Vivek Prakash/Reuters

Novartis’s new gene-modifying cancer therapy’s $475,000 (€399,100) per patient sticker price has drawn fire from advocate groups calling for cheaper d(...)